APGE (Apogee Therapeutics) Cash Flow for Dividends: $0.00 Mil (TTM As of Mar. 2026)


APGE Apogee Therapeutics Inc APGE
12 GF Score
Price $132.69
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics Cash Flow for Dividends?

Apogee Therapeutics APGE -0.14% 12 Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus rates APGE with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Apogee Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Apogee Therapeutics Cash Flow for Dividends Related Terms

Apogee Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Apogee Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apogee Therapeutics Cash Flow for Dividends Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
0.00 0.00 0.00 0.00

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
APGE
12GF Score
Apogee Therapeutics Inc APGE
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $0.00 Mil mean?
Apogee Therapeutics (APGE) has a Cash Flow for Dividends of $0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Apogee Therapeutics and its competitors.
Is Apogee Therapeutics' Cash Flow for Dividends too high?
Apogee Therapeutics' current Cash Flow for Dividends is $0.00 Mil. Overall, Apogee Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' Cash Flow for Dividends compare to MIRM and PTCT?
Apogee Therapeutics' Cash Flow for Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Apogee Therapeutics and its competitors. Apogee Therapeutics's current Cash Flow for Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current Cash Flow for Dividends of $0.00 Mil. The current Cash Flow for Dividends is $0.00 Mil. Apogee Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current Cash Flow for Dividends is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
12GF Score

Get the complete analysis for APGE

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$132.69
Price